Biodexa Pharmaceuticals Plc
Research Biodexa Pharmaceuticals Plc (BDRX) on Bullrun: market cap USD 343.21K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBDRX
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 343.21K
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 6.38M
- Free cash flow-GBP 6.28M
Valuation Snapshot
latest market cap is USD 343.21K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 6.38M | -GBP 6.28M | n/a | -0.5 | GBP 8.53M | GBP 61.00K | GBP 11.41M |
| FY2024 | GBP 0 | -GBP 5.73M | -GBP 13.04M | n/a | -500 | GBP 1.67M | GBP 727.00K | GBP 8.32M |
| FY2023 | GBP 381.00K | -GBP 7.08M | -GBP 7.09M | -967.5% | -10000 | GBP 5.97M | GBP 464.00K | GBP 4.68M |
| FY2022 | GBP 699.00K | -GBP 7.66M | -GBP 7.11M | -631.2% | -400 | GBP 2.84M | GBP 624.00K | GBP 3.16M |
| FY2021 | GBP 578.00K | -GBP 5.46M | -GBP 6.33M | -705.2% | 560 | GBP 10.06M | GBP 766.00K | GBP 10.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 343.21K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.13M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.71M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.04M | n/a | n/a | n/a |
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biodexa Pharmaceuticals Plc's market cap?
Biodexa Pharmaceuticals Plc's market capitalization is USD 343.21K.
What does Biodexa Pharmaceuticals Plc do?
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.